Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
08:10am, Tuesday, 14'th Oct 2025
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
PHOENIX , Oct. 14, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $130 million in growth capital to C
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics aims to transform cancer outcomes
04:47am, Tuesday, 14'th Oct 2025
Deep Dive - Candel Therapeutics Inc
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
10:22am, Monday, 13'th Oct 2025
Candel Therapeutics has generated favorable phase 3 data supportive of a BLA submission in prostate cancer, but it won't come until the end of next year. In the meantime, the market appears to be anti
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
09:05am, Friday, 03'rd Oct 2025
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel trial shows promise for gene therapy in prostate cancer
08:20am, Monday, 29'th Sep 2025
Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
08:05am, Monday, 29'th Sep 2025
NEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
08:05am, Wednesday, 17'th Sep 2025
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics: Potentially The Next Exciting Oncology Story
10:53am, Sunday, 07'th Sep 2025
I rate Candel Therapeutics a Buy, seeing significant upside potential versus current valuation, driven by CAN-2409's blockbuster prospects in immunotherapy oncology. CAN-2409's strong phase III prosta
Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors
12:47pm, Friday, 05'th Sep 2025
Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is fina
Candel Therapeutics adds immunotherapy expert to Research Advisory Board
10:00am, Tuesday, 02'nd Sep 2025
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on viral immunotherapies, announced the appointment of Dr Carl June to its Research Advisory Board. Dr June is
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.
08:05am, Tuesday, 02'nd Sep 2025
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
08:05am, Thursday, 28'th Aug 2025
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics secures RMAT for prostate cancer – ICYMI
09:27am, Saturday, 16'th Aug 2025
Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs
